Santa Rosa Beach, Florida - Medical device incubator and technology brokerage firm, Hatch Medical, L.L.C. (www.hatchmedical.com) announced recently that it has entered into an exclusive brokerage relationship with Syncro Medical Innovations, Inc. and physician inventor, Sabry Gabriel, M.D. to represent their innovative feeding tube technology.
The Gabriel® Feeding Tube with Balloon (GFTB) was developed by Dr. Sabry Gabriel, with $3 MM of combined funding support from the United States Department of Defense and the National Institutes of Health. Based upon recently released market data, the global enteral feeding devices market was valued at approximately $2.8 Billion in 2019 and is projected to reach $4.4 Billion by 2027 at a CAGR of 5.5% from 2020 to 2027. An enteral feeding tube is a medical device used to provide nutrition to those who cannot obtain it by mouth, or are unable to safely swallow, or in need of nutritional supplements.
"Development of the Gabriel® Feeding Tube with Balloon was an iterative and exhaustive process. Millions of dollars were spent on its development, but the end result delivers the most advanced and impactful device on the market today. We are thrilled to be working with Dr. Gabriel to help bring this exciting technology to the market," said Paul Gianneschi, Managing Principal of Hatch Medical.
Due to its unique and patented design, the Gabriel® Feeding Tube with Balloon offers greater opportunities for post-pyloric migration, using the body's natural peristalsis than products without a distally mounted balloon. Additionally, the Gabriel Feeding Tube will not occlude by kinking due to its spiral wire reinforced wall. This feature allows for placement of ample slack in the stomach and feeding without occlusion by kinking. Tube distal migration occurs by the natural effect of peristalsis on the bolus-sized balloon. Syncro Medical's fifth generation, FDA-cleared device provides post-pyloric feeding which can provide significant advantages, including reduced gastro-esophageal reflux and aspiration pneumonia.
In a published clinical study, no undetected misplacement of a tube in the lung or trachea during the insertion procedure and no pneumothorax occurred. This is a function of the effectiveness of the balloon as an early detection feature, preventing inadvertent placement, and using the product's CO2 sampling line and patient's pulse oximetry. A "convenience kit", provided with each device includes a CO2 sampling line, numbing gel and applicator, lubricant gel, a silk suture thread, syringe, skin adhesive and securing tape to save time during bedside placement. The product line is available to interested distributors, or via a technology license or purchase through an exclusive agreement with Hatch Medical.
Dr. Gabriel commented, "We are delighted to have Hatch Medical as our exclusive broker and look forward to identifying a commercial partner committed to bringing our advanced feeding tube products to market."
Hatch Medical jointly develops and brokers minimally invasive medical devices through its network of risk-sharing partners. For additional information on this, or other Hatch Medical, L.L.C. products and services, visit https://www.hatchmedical.com/contact-us/ to contact the company. This release and additional news can be obtained by visiting Hatch Medical's web site: www.hatchmedical.com.
See Campaign: https://www.hatchmedical.com/Contact Information:Name: Paul GianneschiEmail: email@example.comDesignation: Managing PrincipalTags:IPS, Menafn, PR-Wirein, Reportedtimes, Google News, Financial Content, ReleaseLive, Extended Distribution, iCN Internal Distribution, Latin America, English